Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 9, Pages 2471
Publisher
MDPI AG
Online
2023-04-26
DOI
10.3390/cancers15092471
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular mechanisms of Sanguinarine in cancer prevention and treatment
- (2022) Asmat Ullah et al. Anti-Cancer Agents in Medicinal Chemistry
- Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma
- (2022) Guido Bocci et al. Journal of Clinical Medicine
- Optimal biological dose: a systematic review in cancer phase I clinical trials
- (2021) J. Fraisse et al. BMC CANCER
- Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer
- (2021) Bianca Oresta et al. Science Translational Medicine
- Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer
- (2021) Asmat Ullah et al. Cell Death & Disease
- Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer
- (2021) Maryna Bondarenko et al. Cancers
- Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
- (2021) Eleni Skavatsou et al. Cancers
- Metronomic Chemotherapy
- (2021) Marina Elena Cazzaniga et al. Cancers
- Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research
- (2021) Hrishi Varayathu et al. Frontiers in Oncology
- Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies
- (2021) Anindita Chakrabarty et al. Frontiers in Oncology
- Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
- (2020) Hui Zhong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
- (2020) Tamio Okimoto et al. CANCER SCIENCE
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
- (2020) Lorenzo Galluzzi et al. Journal for ImmunoTherapy of Cancer
- Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
- (2020) Luana Schito et al. EMBO Molecular Medicine
- Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion
- (2020) Jeong Uk Choi et al. JOURNAL OF CONTROLLED RELEASE
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
- (2020) Kabir A. Khan et al. npj Breast Cancer
- Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer
- (2020) Li Zhou et al. CANCER LETTERS
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
- (2019) David A. Schaer et al. CLINICAL CANCER RESEARCH
- Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
- (2019) Triparna Sen et al. Journal of Thoracic Oncology
- Metronomic cyclophosphamide induces regulatory T cells depletion and PSA‐specific T cells reactivation in patients with biochemical recurrent prostate cancer
- (2019) Caroline Laheurte et al. INTERNATIONAL JOURNAL OF CANCER
- Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors
- (2018) Paola Orlandi et al. BIOCHEMICAL PHARMACOLOGY
- Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
- (2018) Junjie Wu et al. CANCER LETTERS
- Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
- (2018) Gianfranco Natale et al. CANCER LETTERS
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine
- (2018) Xinqiang Hong et al. Chinese Journal of Cancer Research
- Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
- (2018) Lisanne Noordam et al. OncoImmunology
- Dormancy in cancer
- (2018) Hiroko Endo et al. CANCER SCIENCE
- Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction
- (2018) Emanuele Bruni et al. Frontiers in Pharmacology
- A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
- (2017) Irina Kareva INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Metronomic Cordycepin Therapy Prolongs Survival of Oral Cancer-Bearing Mice and Inhibits Epithelial-Mesenchymal Transition
- (2017) Nai-Wen Su et al. MOLECULES
- Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
- (2017) Annacarmen Petrizzo et al. Oncotarget
- Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development
- (2016) Marina E Cazzaniga et al. Future Oncology
- Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
- (2016) Tze-Sian Chan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effect of low doses of actinomycin D on neuroblastoma cell lines
- (2016) Constanza L. Cortes et al. Molecular Cancer
- Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
- (2015) Irina Kareva et al. CANCER LETTERS
- Abstract 4506: Computational-driven metronomics: application to gemcitabine in neuroblastoma-bearing mice
- (2015) Joseph Ciccolini et al. CANCER RESEARCH
- Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer
- (2015) Tomoharu Miyashita et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine
- (2015) Sébastien Benzekry et al. SEMINARS IN CANCER BIOLOGY
- Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
- (2015) Sabine Taschner-Mandl et al. Oncotarget
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- (2015) Abhishek D. Garg et al. Frontiers in Immunology
- Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory
- (2015) Junjie Wu et al. OncoImmunology
- Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression
- (2015) Chong-Sheng Chen et al. NEOPLASIA
- Metronomics chemotherapy: time for computational decision support
- (2014) Dominique Barbolosi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Adaptive designs for identifying optimal biological dose for molecularly targeted agents
- (2014) Yong Zang et al. Clinical Trials
- A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens
- (2013) C. Faivre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
- (2013) Marta Vives et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells
- (2013) TARANNUM FERDOUS et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Has the time come for metronomics in low-income and middle-income countries?
- (2013) Nicolas André et al. LANCET ONCOLOGY
- Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
- (2013) Ilkka Liikanen et al. MOLECULAR THERAPY
- Mechanisms and insights into drug resistance in cancer
- (2013) Hiba Zahreddine et al. Frontiers in Pharmacology
- Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
- (2012) Eva Ellebaek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
- (2012) Miki Tongu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression
- (2012) J. C. Doloff et al. CANCER RESEARCH
- Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy
- (2012) Mariana S. Nars et al. INTERNATIONAL JOURNAL OF CANCER
- Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
- (2012) Ivan Shevchenko et al. INTERNATIONAL JOURNAL OF CANCER
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner
- (2012) Tillmann Michels et al. Journal of Immunotoxicology
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer
- (2011) Qiushan He et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
- (2010) Federica Moschella et al. Annals of the New York Academy of Sciences
- Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
- (2010) William M. Merritt et al. CANCER BIOLOGY & THERAPY
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
- (2010) G. Schiavoni et al. CANCER RESEARCH
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
- (2010) Rupal Ramakrishnan et al. JOURNAL OF CLINICAL INVESTIGATION
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
- (2009) Claire Banissi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Classification of Chemotherapeutic Agents Based on Their Differential In vitro Effects on Dendritic Cells
- (2009) H. Tanaka et al. CANCER RESEARCH
- The Angiogenic Switch: Implications in the Regulation of Tumor Dormancy
- (2009) L. Moserle et al. CURRENT MOLECULAR MEDICINE
- METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER
- (2009) O.Graciela Scharovsky et al. Current Oncology
- Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
- (2009) G. V. Shurin et al. JOURNAL OF IMMUNOLOGY
- Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
- (2009) Ramon Kaneno et al. Journal of Translational Medicine
- Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'
- (2009) Nicolas André et al. Nature clinical practice. Oncology
- Tumor dormancy of primary and secondary cancers
- (2008) TATURO UDAGAWA APMIS
- Cancer Immunotherapy by Dendritic Cells
- (2008) Cornelis J.M. Melief IMMUNITY
- Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones
- (2008) T.-C. Chou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas
- (2008) R. S. Kerbel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started